Rare Neuro focus Targeting rare and near-rare neuropsychiatric disorders with transdermal cannabinoid therapeutics suggests sales opportunities with patient advocacy groups, specialty clinics, and pharma partners focusing on Fragile X, 22q11.2 Deletion Syndrome, and Autism Spectrum Disorder.

Transdermal Advantage Zygel offers a non-oral, permeation-enhanced CBD gel delivery that may reduce GI-related adverse events and bypass first-pass metabolism, appealing to clinicians prioritizing improved safety profiles for neuropsychiatric patients.

Pipeline Potential A wholly-owned clinical pipeline around Zygel expands cross-border BD opportunities and potential co-development with partners seeking orphan disease access, enabling multi-region licensing or staged collaborations.

Recent Collaborations Equity financing and strategic partnerships (e.g., Lincoln Park Capital Fund) indicate capital readiness and potential for distribution or commercialization alliances, suggesting short- to mid-term BD outreach to investors and distributors.

Market Position Leadership in pharmaceutically-produced transdermal cannabinoid therapies for rare disorders positions Zynerba as a potential partner for specialty distributors, clinics, and payer negotiations seeking differentiated, targeted CNS therapies.